Catalyst Wire Dossier Catalyst Wire Dossier

Tifcemalimab

tifcemalimab · Shanghai Junshi Bioscience Co., Ltd.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Tifcemalimab, covering 2024-06-21 to 2024-12-27. Get the full timeline:

Most recent: Clinical Trial Update: Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC [Phase 1]

See pricing